In support of this line of reasoning, clinical trials have demonstrated a higher clinical benefit in patients treated with aromatase inhibitors compared to those treated with tamoxifen alone [87] and recommendations have been made to incorporate an AI to reduce the risk of breast cancer recurrence [74]. The gene discussed is CYP19A1; the disease is breast carcinoma.